Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 57,419	$ 84,675	$ 103,112	$ 139,825
Royalties
Disaggregation of Revenue [Line Items]
Total revenue	17,959	8,616	31,654	15,728
Kyprolis
Disaggregation of Revenue [Line Items]
Total revenue	7,127	5,440	11,749	9,727
Evomela
Disaggregation of Revenue [Line Items]
Total revenue	2,394	2,193	5,095	4,526
Teriparatide injection
Disaggregation of Revenue [Line Items]
Total revenue	5,502	264	8,413	264
Rylaze
Disaggregation of Revenue [Line Items]
Total revenue	2,317	0	3,966	0
Other
Disaggregation of Revenue [Line Items]
Total revenue	619	719	2,431	1,211
Captisol
Disaggregation of Revenue [Line Items]
Total revenue	29,545	62,509	41,667	93,781
Captisol - Core
Disaggregation of Revenue [Line Items]
Total revenue	3,325	9,682	9,551	10,935
Captisol - COVID
Disaggregation of Revenue [Line Items]
Total revenue	26,220	52,827	32,116	82,846
Contract
Disaggregation of Revenue [Line Items]
Total revenue	9,915	13,550	29,791	30,316
Service Revenue
Disaggregation of Revenue [Line Items]
Total revenue	5,453	7,360	10,599	12,822
License Fees
Disaggregation of Revenue [Line Items]
Total revenue	1,608	1,050	4,694	2,093
Milestone
Disaggregation of Revenue [Line Items]
Total revenue	1,275	3,600	10,364	12,017
Other
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,579	$ 1,540	$ 4,134	$ 3,384